“…As survival rates continue to improve, it is important to understand how MB treatments affect survivors’ cognitive and psychological functioning and therefore, overall quality of life (Margelisch et al, ; Zeltzer et al, ). Children who receive treatments targeting the central nervous system, such as MB patients, are at an increased risk of developing cognitive late effects in comparison with survivors of other types of childhood cancer (Conklin et al, ; Olson & Sands, ; Palmer et al, ). Evidence indicates that age at treatment (i.e., younger), longer time since diagnosis, female gender, treatment intensity, type of chemotherapy (especially methotrexate), craniospinal irradiation, perioperative complications and possibly hydrocephalus, increase the risk of low cognitive functioning after treatment (Margelisch et al, ).…”